Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 1.74B P/E 8.68 EPS this Y 620.00% Ern Qtrly Grth -99.70%
Income -6.39M Forward P/E -54.16 EPS next Y 96.20% 50D Avg Chg 5.00%
Sales 232.28M PEG - EPS past 5Y - 200D Avg Chg 18.00%
Dividend N/A Price/Book 3.09 EPS next 5Y - 52W High Chg -23.00%
Recommedations 2.00 Quick Ratio 12.67 Shares Outstanding 130.86M 52W Low Chg 44.00%
Insider Own 0.31% ROA -1.92% Shares Float 123.06M Beta 1.28
Inst Own 98.02% ROE -1.06% Shares Shorted/Prior 17.97M/16.37M Price 13.54
Gross Margin 55.88% Profit Margin -2.75% Avg. Volume 1,627,985 Target Price 25.75
Oper. Margin -11.69% Earnings Date Apr 30 Volume 3,183,539 Change -1.96%
About Dynavax Technologies Corporatio

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; Biological E. Limited; PT Bio Farma; Medigen Vaccine Biologics; and Serum Institute of India Pvt. Ltd. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. The company was incorporated in 1996 and is headquartered in Emeryville, California.

Dynavax Technologies Corporatio News
03/25/24 Those who invested in Dynavax Technologies (NASDAQ:DVAX) five years ago are up 68%
03/04/24 Chief Accounting Officer Justin Burgess Sells Shares of Dynavax Technologies Corp (DVAX)
03/04/24 11 Best Small Cap Pharma Stocks to Invest In
02/27/24 Dynavax to Present at TD Cowen's 44th Annual Health Care Conference
02/23/24 Dynavax Technologies Corporation (NASDAQ:DVAX) Q4 2023 Earnings Call Transcript
02/23/24 Q4 2023 Dynavax Technologies Corp Earnings Call
02/22/24 Dynavax Technologies (DVAX) Q4 2023 Earnings Call Transcript
02/22/24 Dynavax Technologies (DVAX) Reports Break-Even Earnings for Q4
02/22/24 Dynavax Technologies Corp (DVAX) Reports Robust Revenue Growth and Market Leadership in 2023
02/22/24 Dynavax Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Full Year 2024 Financial Guidance
02/08/24 Dynavax to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on February 22, 2024
01/08/24 3 Stocks Set to Soar 68% to 200% Higher
01/08/24 Dynavax Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Financial Highlights
01/05/24 Dynavax Technologies (DVAX) Is a Great Choice for 'Trend' Investors, Here's Why
01/05/24 Insider Sell: Dynavax Technologies Corp President & COO David Novack Sells 9,000 Shares
01/04/24 Collegium (COLL) Shares Rise on Financial Outlook for 2024
01/04/24 Assertio (ASRT) Shares Fall as Dan Peisert Steps Down as CEO
01/03/24 Dynavax to Present at the 42nd Annual J.P. Morgan Healthcare Conference
01/03/24 Is Dynavax Technologies Corporation's (NASDAQ:DVAX) Recent Stock Performance Influenced By Its Financials In Any Way?
01/03/24 C4 Therapeutics (CCCC) Gains 310% in 3 Months: Here's Why
DVAX Chatroom

User Image HRHKK Posted - 10 hours ago

$DVAX Dyna junk

User Image Smac57 Posted - 11 hours ago

$DVAX This garbage is so bad Waste Management won't even take it to the dump.

User Image martycar97 Posted - 19 hours ago

$DVAX A growing product that is best in class, a load of cash, and a versatile adjuvant that can be used in many applications. A big pharma needs to snatch this gem up!

User Image Night_Owl_Biotech Posted - 1 day ago

We track the share prices of 12 biopharmas that are primarily focused on vaccine therapies. The attachment notes the share prices of the subject 12 since year end. We are only aware of Iscovax that was recently acquired. 11 of the 12 are trading lower year to date. Please let us know if we are missing any biopharmas primarily, again primarily, focused on developing vaccine therapies. We are aware of those with vaccines in their portfolio like AGEN. As always, our data could be wrong. Thank you. $HLVX $PCVX $DVAX $ARCT $NVAX

User Image legendairy Posted - 2 days ago

$DVAX does anybody know a tool that shows institutional $average?

User Image KWalzz Posted - 2 days ago

$DVAX next big "thang" here? QE on April, 30th (or May, 7th) ... 10-Q and 8-K. And then 2 or 3 days later the first Form 4s and 144s.

User Image Dvax2theMoon Posted - 3 days ago

$DVAX single digits again soon most likely

User Image KWalzz Posted - 3 days ago

$DVAX there should be the outcome of Phase II of the plague vaccine in April 2024. I doubt it because they have already worked so hard regarding compensation and dilution, but we will see. no matter how this develops this is becoming more and more a dead investment ...

User Image AccuRoger Posted - 3 days ago

$DVAX The Proxy Statement for the Annual Meeting is released. Let the crying begin over Eleven million shares. My perspective is this is normal and protects the Cash position that generates 5%/year. Quote: To approve the amendment and restatement of the Dynavax Technologies Corporation 2018 Equity Incentive Plan to, among other things, increase the aggregate number of shares of common stock authorized for issuance under the plan by 11,400,000. To approve, on an advisory basis, the compensation of the Company’s named executive officers, as disclosed in the proxy statement accompanying this Notice.

User Image KWalzz Posted - 3 days ago

$DVAX they will increase common stock by "only" 11,400,000 shares ... yes, this is what ARS tells. so dilution will most likely go on on heavier scale than I thought ... sad development so far.

User Image KWalzz Posted - 3 days ago

$DVAX yep, ARS was filed on Apr,11 ... see dynavax sec filings.

User Image HeadlessHorsemen Posted - 4 days ago

$DVAX I'm about to snore over how boring this stock is, but before I begin to snore, I start to cry over the incompetency of the Board and the Administration of this company.

User Image Buy_dvax100 Posted - 4 days ago

$DVAX

User Image canesmonkey Posted - 4 days ago

$DVAX Ugghhh this range bound and drop is getting very old

User Image KWalzz Posted - 5 days ago

$DVAX next "big" developments here? ARS is due tomorrow or next thursday ... then few weeks later more Form 4s and 144s?

User Image KWalzz Posted - 5 days ago

$DVAX short interest up again (what else) ... see nasdaq.

User Image martycar97 Posted - 6 days ago

$DVAX

User Image VictorJung Posted - 1 week ago

$DVAX has anyone figured out what happened to our pipeline? shingles? any sightings?

User Image Wolfofwannabe Posted - 1 week ago

$DVAX Trending

User Image KWalzz Posted - 1 week ago

$DVAX we may see share price action - maybe upwards & of course only by chance if at all ... 💩 https://investors.dynavax.com/node/20821/html

User Image charlapp Posted - 1 week ago

$DVAX If price action is constrained at $12 indefinitely, I’m inclined to shift my investment to more lucrative biotechs with actual momentum. $ENTX and $AQST both have drugs in phase 3 trials.

User Image KWalzz Posted - 1 week ago

$DVAX and about financial strength accd to gf:

User Image KWalzz Posted - 1 week ago

$DVAX here as a reminder the insider SALES and BUYS (😂)

User Image KWalzz Posted - 1 week ago

$DVAX here the chart that shows "how management has performed" ...

User Image KWalzz Posted - 1 week ago

$DVAX and another one from YMB ... #2:

User Image KWalzz Posted - 1 week ago

$DVAX from over at YMB ... #1:

User Image KWalzz Posted - 1 week ago

$DVAX no one cares ....

User Image AccuRoger Posted - 1 week ago

$DVAX The Proxy Statement for the end of May Annual Meeting and vote for Directors is normally released in mid-April without a PR notice under SEC reports. There is apt to be a request to increase shares to cover Management compensation. This is normal and Institutional Investors will approve it. Cry if you have to. The more important detail is in the goal statements that may or may not provide insight to the future of the company. Sometimes they are so generic that it is a waste to read them. To Be Determined, probably by the end of next week.

User Image AccuRoger Posted - 1 week ago

$DVAX New CpG 1018 trial is recruiting for a Zika vaccine. Paid by Valneva. https://clinicaltrials.gov/study/NCT06334393?intr=CpG1018&aggFilters=status:not%20rec%20act&rank=3

User Image Smac57 Posted - 1 week ago

$DVAX Someone bet big on the $12 Puts for Apr 19...

Analyst Ratings
Goldman Sachs Neutral Feb 1, 24
JMP Securities Market Outperform Nov 3, 23
HC Wainwright & Co. Buy Nov 3, 23
HC Wainwright & Co. Buy Aug 4, 23
JMP Securities Outperform Aug 4, 23
JMP Securities Outperform May 3, 23
HC Wainwright & Co. Buy May 3, 23
JMP Securities Market Outperform Feb 24, 23
HC Wainwright & Co. Buy Feb 24, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Janssen Robert SVP and CMO SVP and CMO Jan 04 Sell 15 1,500 22,500 49,925 01/08/24
Janssen Robert SVP and CMO SVP and CMO Jan 04 Option 9.41 1,500 14,115 51,425 01/08/24
Novack David F President & COO President & COO Jan 02 Sell 14.45 9,000 130,050 3,187 01/04/24
Novack David F President & COO President & COO Jan 02 Option 5.42 9,000 48,780 12,187 01/04/24
Novack David F President & COO President & COO Dec 01 Sell 13.56 20,000 271,200 3,187 12/05/23
Novack David F President & COO President & COO Dec 01 Option 5.42 20,000 108,400 23,187 12/05/23
Novack David F President & COO President & COO Nov 03 Sell 15 20,000 300,000 3,187 11/07/23
Novack David F President & COO President & COO Nov 03 Option 5.42 20,000 108,400 23,187 11/07/23
Janssen Robert SVP and CMO SVP and CMO Oct 10 Sell 15.01 1,755 26,343 49,925 10/11/23
Janssen Robert SVP and CMO SVP and CMO Oct 10 Option 9.41 1,755 16,515 51,680 10/11/23
Janssen Robert SVP and CMO SVP and CMO Oct 02 Option 9.41 5,015 47,191 54,940 10/03/23
Janssen Robert SVP and CMO SVP and CMO Oct 02 Sell 15.03 5,015 75,375 49,925 10/03/23
Novack David F President & COO President & COO Sep 01 Sell 14.48 20,000 289,600 3,187 09/05/23
Novack David F President & COO President & COO Sep 01 Option 5.42 20,000 108,400 23,187 09/05/23
Janssen Robert SVP and CMO SVP and CMO Aug 24 Sell 15.02 600 9,012 49,925 08/25/23
Janssen Robert SVP and CMO SVP and CMO Aug 24 Option 9.41 600 5,646 50,525 08/25/23
Janssen Robert SVP and CMO SVP and CMO Aug 23 Sell 15.01 34,857 523,204 49,925 08/24/23
Janssen Robert SVP and CMO SVP and CMO Aug 23 Option 9.41 34,857 328,004 84,782 08/24/23
Novack David F President & COO President & COO Aug 08 Sell 14.83 40,000 593,200 3,187 08/10/23
Novack David F President & COO President & COO Aug 08 Option 4.62 40,000 184,800 43,187 08/10/23
Janssen Robert SVP and CMO SVP and CMO Aug 08 Sell 15.05 2,600 39,130 49,925 08/09/23
Janssen Robert SVP and CMO SVP and CMO Aug 08 Option 9.41 2,600 24,466 52,525 08/09/23
Novack David F President & COO President & COO May 04 Sell 10.90 17,515 190,914 3,187 05/05/23
Novack David F President & COO President & COO Nov 08 Sell 12.47 52,204 650,984 2,066 11/10/22
Hack Andrew A. F. Director Director Aug 15 Sell 14.68 3,000,000 44,040,000 5,415,000 08/17/22
Janssen Robert Senior Vice Presiden.. Senior Vice President Aug 08 Sell 16.92 7,938 134,311 35,519 08/10/22
Novack David F President & COO President & COO Aug 08 Sell 16.92 26,250 444,150 53,213 08/10/22
Spencer Ryan CEO and Director CEO and Director Aug 08 Sell 16.92 14,921 252,463 144,513 08/10/22
CANO FRANCIS Director Director Aug 08 Option 4.97 15,000 74,550 35,834 08/10/22
CANO FRANCIS Director Director Aug 08 Sell 17.17 15,000 257,550 20,834 08/10/22
Burgess Justin Chief Accounting Off.. Chief Accounting Officer Aug 08 Option 7.42 18,672 138,546 22,526 08/09/22
Burgess Justin Chief Accounting Off.. Chief Accounting Officer Aug 08 Sell 16.72 18,672 312,196 3,854 08/09/22
Janssen Robert Senior Vice Presiden.. Senior Vice President Aug 05 Option 10.47 5,350 56,014 29,157 08/09/22
Janssen Robert Senior Vice Presiden.. Senior Vice President Aug 05 Sell 17.09 5,350 91,432 24,707 08/09/22
Novack David F President & COO President & COO Aug 05 Sell 16.00 20,000 320,000 53,213 08/09/22
Burgess Justin Principal Accounting.. Principal Accounting Officer May 16 Sell 10 6,000 60,000 3,854 05/18/22
Novack David F President & COO President & COO Mar 02 Sell 10.57 41,862 442,481 73,213 03/04/22
Spencer Ryan CEO and Director CEO and Director Mar 02 Sell 10.57 83,108 878,452 129,771 03/04/22
Janssen Robert Senior Vice Presiden.. Senior Vice President Mar 02 Sell 10.57 24,036 254,061 24,707 03/04/22
Burgess Justin Principal Accounting.. Principal Accounting Officer Mar 02 Sell 10.58 21,490 227,364 3,854 03/04/22
Hack Andrew A. F. Director Director Aug 27 Sell 16.22 2,000,000 32,440,000 8,415,000 08/27/21
Novack David F President & COO President & COO Aug 25 Sell 14 10,000 140,000 104,066 08/25/21
Novack David F President & COO President & COO Aug 25 Option 4.5 4,167 18,752 114,066 08/25/21
Burgess Justin Principal Accounting.. Principal Accounting Officer Aug 25 Sell 15 5,768 86,520 3,721 08/25/21
Burgess Justin Principal Accounting.. Principal Accounting Officer Mar 26 Sell 8.86 4,144 36,716 6,989 03/26/21
Burgess Justin Principal Accounting.. Principal Accounting Officer Mar 02 Sell 8.86 4,123 36,530 7,010 03/02/21